Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
August 20, 2025
These are averages from study populations
Part I: Diagnosis
SURMOUNT-1 (NCT04184622) Study Title: "Tirzepatide Once Weekly for the Treatment of Obesity" Status: Completed Phase: Phase 3 Enrollment: 2,539 participants Study Period: 2019-2021 Location: Multi-national, 119 sites Design: Randomized, double-blind, placebo-controlled Duration: 72 weeks Intervention: Tirzepatide 5/10/15 mg SC weekly vs
AOD-9604 weight loss peptide also has joint regeneration capabilities Although AOD-9604 is primarily known for its weight loss properties, its regenerative potential cannot be overlooked
US$ 21.95
US$ 28.34
US$ 21.53
US$ 24.01
